Another indication was that administration of anti-OX40-mAbs before engraftment of the tumor rendered Tregs functionally inactive by inhibiting IL-10 production and eliminating Treg-mediated suppression of the CD8 T-cell response. Here, TNFRSF4 is linked to neoplasm.